返回首页 | 关于我们 | 设为主页 | 加入收藏
来福赛思--首页 公司简介 产品展示 新闻动态 技术专栏 在线留言 人才招聘 联系我们  
北京来福赛思科技有限公司 北京来福赛思科技有限公司
 
诊断试剂原辅料
疫苗生产原辅料
基因制药原辅料
细胞培养原辅料
微生物检测产品
常用仪器及耗材
WHO国际标准物质
 
站内信息搜索
关键字:
栏目导航:
 
技术专栏
 
应对恶性SIV感染的疫苗
发布日期:2013-10-08      浏览:3013

关键词: 疫苗 恶性SIV感染 免疫

有关用于“人免疫缺陷病毒”(HIV)和“猿免疫缺陷病毒”(SIV)的潜在疫苗的研究工作迄今为止基本上都没有什么成果。这项研究取得了一些进展,因为它利用了最近的一项发现:在感染后的前几个小时到几天时间里,这些病原体似乎对免疫控制或药理清除是脆弱的。用表达SIV病毒的恒河猴巨细胞病毒载体接种的恒河猴,在经过阴道和静脉途径染毒后,对高致病性SIVmac239病毒形成了耐久性抵抗力。一些接种的动物将病毒复制控制了1-3年时间,没有明显证据表明有残留病毒,这提出了一个可能性:由疫苗诱导的免疫反应事实上可能已经消除了最初的感染。

推荐英文摘要

Nature  doi:10.1038/nature12519

Immune clearance of highly pathogenic SIV infection

Scott G. Hansen,  Michael Piatak Jr,  Abigail B. Ventura,  Colette M. Hughes,  Roxanne M. Gilbride,  Julia C. Ford,  Kelli Oswald,  Rebecca Shoemaker,  Yuan Li,  Matthew S. Lewis, Awbrey N. Gilliam,  Guangwu Xu,  Nathan Whizin,  Benjamin J. Burwitz,  Shannon L. Planer, John M. Turner,  Alfred W. Legasse,  Michael K. Axthelm,  Jay A. Nelson,  Klaus Früh,  Jonah B. Sacha,  Jacob D. Estes,  Brandon F. Keele,  Paul T. Edlefsen,  Jeffrey D. Lifson  & Louis J. Picker

Established infections with the human and simian immunodeficiency viruses (HIV and SIV, respectively) are thought to be permanent with even the most effective immune responses and antiretroviral therapies only able to control, but not clear, these infections1, 2, 3, 4. Whether the residual virus that maintains these infections is vulnerable to clearance is a question of central importance to the future management of millions of HIV-infected individuals. We recently reported that approximately 50% of rhesus macaques (RM; Macaca mulatta) vaccinated with SIV protein-expressing rhesus cytomegalovirus (RhCMV/SIV) vectors manifest durable, aviraemic control of infection with the highly pathogenic strain SIVmac239 (ref. 5). Here we show that regardless of the route of challenge, RhCMV/SIV vector-elicited immune responses control SIVmac239 after demonstrable lymphatic and haematogenous viral dissemination, and that replication-competent SIV persists in several sites for weeks to months. Over time, however, protected RM lost signs of SIV infection, showing a consistent lack of measurable plasma- or tissue-associated virus using ultrasensitive assays, and a loss of T-cell reactivity to SIV determinants not in the vaccine. Extensive ultrasensitive quantitative PCR and quantitative PCR with reverse transcription analyses of tissues from RhCMV/SIV vector-protected RM necropsied 69–172 weeks after challenge did not detect SIV RNA or DNA sequences above background levels, and replication-competent SIV was not detected in these RM by extensive co-culture analysis of tissues or by adoptive transfer of 60 million haematolymphoid cells to naive RM. These data provide compelling evidence for progressive clearance of a pathogenic lentiviral infection, and suggest that some lentiviral reservoirs may be susceptible to the continuous effector memory T-cell-mediated immune surveillance elicited and maintained by cytomegalovirus vectors.

 
首 页     |     公司简介     |     产品展示     |     特价促销    |     新闻动态    |     技术专栏    |     在线留言     |     人才招聘     |     联系我们     |     企业邮箱
联系经理
Merck ThermoFisher Bovogen Fitzgerald biospacific bbisolutions meridianlifescience bioventix Diasource EastCoastBio mybiosource calbioreagents ProSpec Nittobo/IIC-MBC Icl medix leebio 德国progen Genwaybio Norwegian Antibodies lumigen PolyMicrospheres magsphere biorbyt southernbiotech Abcam Rabios Abbexa Sdix Capricorn Apollo OXOID acros SERVA Seramun cygnustechnologies generalchemical ChemTrade Pharmacosmos Corning Axygen nibsc NIST IRMM标准品 edqm JCCRM
联系经理
©2012 北京来福赛思科技有限公司 Tel:010 8174 3370 Fax:010 8174 3370 MP:136 4103 4192 Mail:info@bj-life-science.com 京ICP备15009805号-1